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Abstract: Objective: The principle of management of patients with oligometastasis is evolving. The current study 
aims to investigate theefficacy of percutaneous radiofrequency ablation (RFA) of the solitary liver metastasis after 
previous radiotherapy for nasopharyngeal carcinoma (NPC). Methods: A pilot study involving 4 patients with 
biopsy proven solitary liver metastasis from NPC. After creation of artificial ascites, cooltip RFA needle was 
inserted into the intra-hepatic  tumor  under  ultrasound  guidance.  Procedure  related  complications  were  noted  
and  patients  were followed up regularly and indefinitely for oncological outcome. Results: All patients had 
locoregionally advanced NPC at initial diagnosis and were treated with concurrent chemoradiation. Complete 
response was achieved in all patients. The mean time to tumor recurrence was 21.3 months. The mean size of the 
liver tumor was 3.5cm. Two patients had synchronous local tumor recurrence, and they underwent 
nasopharyngectomy and neck dissection before receiving treatment to the liver. Percutaneous RFA was performed in 
all patients. The mean hospital stay was 2.2 days and no procedure related complications were detected. No 
systemic treatment was given afterwards. The mean follow-up interval was 40.5 months. One of the patients 
developed progression of disease and died at 13 months after RFA, while the rest of the patients were alive and 
2 
JNPC  ★ http://www.journalofnasopharyngealcarcinoma.org/ Published: 2016-02-15  ★ DOI:10.15383/jnpc.30 e-ISSN 2312-0398 
 
 
remained disease free at the last follow-up. Conclusion: Percutaneous RFA is potentially useful as a minimally 
invasive procedure for patients with solitary liver metastasis after radiotherapy for NPC. Further study is required to 
confirm its efficacy and to define the protocol of adjuvant systemic chemotherapy to improve the treatment outcome. 
Keywords: Nasopharyngeal carcinoma; Recurrent; Distant metastasis; Oligometastasis; Survival 
 
 
 
 
 
 
Introduction 
 
 
Southern China and Hong Kong is one of the endemic areas where 
the incidence of nasopharyngeal carcinoma (NPC) is among the 
highest in the world
[1]
. Unfortunately, more than 50% of the patients 
present with stage III-IVB disease, according to the American Joint 
Committee on Cancer (AJCC, 6
th 
edition)
[2]
. In the presence of 
locoregionally  advanced  tumor,  the  use  of  concurrent 
chemoradiation was shown to be superior compared to radiotherapy 
alone, either in terms of improvement in local and regional control 
 
 
[3-5]
, or reduced risk of distant failure
[3, 6-7]
. In a study involving 256 
patients with NPC, the incidence of systemic metastasis was up to 
36%
[8]
, the most common sites of which being the bones, lungs and 
the liver. Data on the treatment of distant failures after radiotherapy 
for NPC is limited. At the moment, treatment in such circumstances 
is mainly palliative in nature, which usually consists of the use of 
combination chemotherapy. 
Trans-arterial chemo-embolization (TACE) has been used in the 
treatment of liver metastasis
[9]
, although its efficacy has not been 
properly studied in NPC. In a recent study of 15 patients with TACE 
performed for liver metastasis from NPC
[10]
, the 1-, 3- and 5-year 
progression free survival rates were 27%, 7% and 0%, respectively, 
and the median survival was 4.2 months. Hepatectomy results in a 
significantly better survival rates and median survival. However, the 
corresponding post-operatively morbidities are not insignificant, 
 including pain, fever, and hepatic insufficiency, leading to a longer 
hospital stay. The aim of the current report is to investigate the role 
of percutaneous radiofrequency ablation (RFA) as a minimally 
invasive procedure for patients with oligometastasis in the liver after 
previous chemoradiotherapy for NPC. 
Patients and Methods 
 
 
The present study was approved by the Institutional Review Board 
of  the  University of  Hong  Kong/Hospital  Authority  Hong  Kong 
West Cluster. Between 2006 and 2010, four patients were referred to 
the Division of Head and Neck Surgery, Department of Surgery, 
Queen  Mary  Hospital,  the  University  of  Hong  Kong,  for  the 
treatment of recurrent NPC with oligometastasis involving the liver. 
Clinical data that were retrieved from the Head and Neck Cancer 
Database included the demographic information, initial and recurrent 
tumor   stage   (AJCC   6
th     
Edition),   plasma   Epstein-Barr   virus 
 
 
Deoxyribonucleic acid (EBV DNA) level before and after treatment, 
complication and disease status. 
Pre-treatment Assessment 
 
 
Flexible nasoendoscopy was routinely performed under topical 
anaesthesia and any suspicious area would be biopsied for 
histological confirmation. In patients whose tumor was entirely 
located in the submucosal plane, examination under anaesthesia and 
deep  biopsy  after  incising  the  overlying  nasopharyngeal  mucosa 
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would be performed. Plasma Epstein-Barr virus (EBV)-DNA level 
was measured with real-time quantitative PCR, which identified the 
Bam  HI-W  fragment  region  of  the  EBV  genome
[11]
.  Contrast 
magnetic resonance imaging (MRI) from the skull base to the neck 
 
 
was crucial to assess the locoregional extent of the tumor, if present. 
Computer  tomography  (CT)  of  the  hepatobiliary  system  with 
contrast was performed to assess the number and location of the 
intra-hepatic metastatic tumors, as well as the relationship of the 
tumor to vital structures, including the diaphragm, bile ducts and the 
major  vasculatures.   CT  guided   fine  needle   aspiration   of  the 
intra-hepatic tumors were performed. PET scan was required to rule 
out the presence of metastatic tumors in other organs apart from the 
liver. 
Exclusion criteria included the presence of simultaneous and 
unresectable loco-regional tumors, more than one intra-hepatic 
metastatic lesion, tumor in close proximity to the major bile ducts, 
hepatic and portal veins, biochemical or radiological liver cirrhosis, 
and the presence of metastatic tumors in other organs apart from the 
liver. A multidisciplinary meeting would be held with the 
participation of surgeons, clinical oncologists, radiologists as well as 
the patients and their relatives. 
Treatment of Loco-Regional Recurrent NPC 
If pre-treatment investigation confirmed the presence of locoregional 
recurrence, surgical salvage will be performed before the treatment 
of the liver metastasis. The local tumor in the nasopharynx was 
resected via the maxillary swing approach
[12]
. The Weber Ferguson 
Longmire incision ipsilateral to the nasopharyngeal tumor was used.  
After  osteotomy,  the  maxilla  was  swung  out,  providing  spacious 
 access to allow resection of the tumor with wide margins. Frozen 
section examination was employed to make sure the resection 
margins were histologically clear of tumor. Afterwards, the maxilla 
was returned and fixed with titanium mini-plates and screws. In 
patients   with   nodal   metastasis,   radical   neck   dissection   was 
performed. 
Radiofrequency Ablation of Liver Metastases 
 
 
The procedure was performed under sedation using intravenous 
injection of pethidine (50mg) and midazolam (10-15mg). Artificial 
ascites was induced by intra-peritoneal injection of normal saline 
solution.  Afterwards,  cooltip  RFA  needle  was  inserted  into  the 
intra-hepatic tumor under ultrasound guidance (Figure 1). Real time 
ultrasound monitoring was performed during the delivery of energy. 
After ablation, intensive monitoring of the haemodynamic status was 
provided in the ward. Blood test for liver function and haemoglobin 
was checked 6 hours and 12 hours after the procedure. 
Post-operative Follow-up 
 
 
In view of the small volume of recurrent disease and in order to 
examine the efficacy of percutaneous RFA in disease control, no 
adjuvant systemic chemotherapy was given in our patients. After 
discharge from the hospital, endoscopic examination was performed 
monthly at the out-patient clinic for the first post-operative year, 
which was spaced out gradually afterwards. Therapeutic response of 
metastatic liver tumor to RFA was assessed by plasma EBV DNA 1 
month after the procedure. It was then serially measured 6 monthly 
afterwards to monitor the disease status. MRI examination of the 
nasopharynx and CT scan of the liver was performed every 6 months 
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Figure 1. (Left) CT scan showed the presence of solitary liver metastasis (black arrow) measuring 3.2cm in size, located at segment 5 of the liver. (Middle) Before the 
start of RFA, artificial ascites (white arrow) was created by intra-peritoneal injection of normal saline solution. This was especially import for tumors located in the 
dome of the liver to prevent collateral damage to the ipsilateral diaphragm. (Right) Afterwards, cooltip RFA needle was inserted under ultrasound guidance. During 
the delivery of energy, real time ultrasound monitoring was performed. 
 
 
 
for the first 2 years to detect tumor recurrence, and then yearly 
afterwards. 
Results 
 
 
Patient Characteristics: During the study period, 12 patients were 
found to have liver metastasis after previous radiotherapy for NPC. 
Eight patients were excluded from the study (multiple organs with 
distant metastasis, n = 6; multiple metastatic tumors involving both 
lobes of the liver, n = 2), while the remaining 4 patients with 
oligometastasis of the liver were recruited into the study. The 
patient and tumor characteristics were shown in Table 1. All of 
them were male. Their age ranged from 34 to  55  years. There 
were 2  patients  with initially Stage  II and  2 patients with Stage 
III according to American Joint Committee on Cancer (AJCC, 6
th
 
edition).One patient received induction chemotherapy followed by 
concurrent chemoradiation, while the rest received concurrent 
chemoradiotherapy alone. None of the patients received  adjuvant  
chemotherapy  after  the  radical  treatment.  The mean time of 
diagnosis of tumor recurrence from the completion of radiotherapy 
was 21.3 months. All tumors were non-keratinizing, 
undifferentiated type. The mean plasma EBV DNA level was 442.5 
copies / mL (range, 214 to 845 copies / mL). 
Two patients had simultaneous tumor recurrence in the nasopharynx 
and one of them had ipsilateral nodal metastasis as well. These two 
patients underwent surgical salvage for the locoregional tumors 
before treatment of the liver metastases. Both patients had complete 
resection of tumors with microscopically clear resection margins. 
Mean hospital stay was 9.5 days (7 to 12 days, respectively) and 
there was no hospital mortality. The mean interval from surgery to 
RFA for the metastatic liver tumors was 6 weeks. 
All the patients had USG guided tru-cut biopsy of the liver tumors and 
they were confirmed to be metastatic undifferentiated carcinoma. The 
characteristics of the liver tumors were shown in Table II. The mean 
size of the tumors was 3.5 ± 0.9 cm (range, 2.8 to 4.4 cm). All the 
patients received RFA of the liver tumors under sedation. The mean 
duration of the procedure was 14 ± 2.4 minutes (range, 12 – 16 
minutes). The mean hospital stay after the procedure was 2.2 days. 
None of the patients had derangement of liver function or developed 
complications related to the procedure performed to the liver tumors. 
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Table 1  Patients’ clinical characteristics. 
 
 
 Patient 1 Patient 2 Patient 3 Patient 4 
Age 34 38 45 55 
Sex M M M M 
Initial NPC stage * T3N3M0 T2N1M0 T2N1M0 T3N2M0 
Initial treatment protocol Induction CT + CTRT CTRT CTRT CTRT 
Time to recurrence 
(months) 
14 32 23 16 
Recurrent NPC stage * T2N1M1 T0N0M1 T0N0M1 T1N0M1 
Pre-treatment pEBV DNA level 
(copies / mL) 
845 344 214 367 
* American Joint Committee on Cancer ([AJCC], 6th edition . 
 
Abbreviations: CT, chemotherapy; CTRT, chemoradiotherapy; pEBV DNA: plasma Epstein-Barr virus deoxyribonucleic acid 
 
 
 
The mean follow-up of the patients was 40.5 months. One patient was 
diagnosed of multiple bone and bilateral pulmonary metastases at 11 
months after RFA and died subsequently from complications of 
palliative chemotherapy at 13 months after RFA. The rest of the 
patients were alive and remained disease free at last follow-up. Their 
pEBV DNA remained undetectable. 
Discussion 
High incidence of distant metastasis in patents with NPC has long 
been recognized. It remained the major cause of death, despite the 
improving locoregional control. Two decades ago, a retrospective 
review and an autopsy study of patients with NPC has found that the 
overall incidence of distant metastasis was 36%
[13]
. In the report, liver 
was the most common site of involvement. The authors found a strong 
correlation with the presence of advanced locoregional disease on 
presentation. In another study involving 629 patients with NPC, the 
chance of distant metastasis was 19.8%
[14]
, among whom, 75% had 
bone metastasis, 46% had lung metastasis, 38% had liver metastasis, 
 
 
10% had retroperitoneal nodal metastasis, and 57% of these patients 
had multiple organs involvement. Majority (95%) of the patients had 
the distant metastases diagnosed within 3 years after the completion of 
radiotherapy [first year (52%), the second year (23%) and the third 
year (20%)]. The median survival from the diagnosis of distant 
metastasis was poor, ranging from 3.2 months for hepatic metastasis, 
11.2 months for bone metastasis, to 16.3 months for pulmonary 
metastasis. 
With improving techniques of radiotherapy and the availability of new 
chemotherapeutic agents, treatment of distant metastasis from NPC 
has been revisited. Prolonged survival of over 82 months was reported 
in a patient with lung metastasis after radiotherapy for NPC
[15]
. In this 
patient, an intensive chemotherapy regimen was given, including a 
 
 
continuous    four-day    infusion    of    cisplatin    (20    mg/m2/day), 
 
 
5-fluorouracil (2200 mg/m2/day) and leucovorin (120 mg/m2/day) 
every 4 weeks, leading to almost complete disappearance of the lung 
lesions. In another report, a patient with solitary liver metastasis was 
treated with neoadjuvant chemotherapy and subsequent concurrent 
chemoradiotherapy, followed by surgical resection of the liver tumor 
with segmentectomy. Early assessment at 6-months after surgery 
showed no signs of local recurrence in the liver or progression of 
distant metastasis
[16]
. In a subsequent study, 15 patients with liver 
 
 
metastasis from NPC were treated by partial hepatectomy, and  the 
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Table 2. Clinical data and outcome of percutaneous radiofrequency frequency ablation of liver metastasis after radiotherapy for NPC 
 
 
 Patient 1 Patient 2 Patient 3 Patient 4 
Size of live tumor 3.2 2.8 4.4 3.6 
Location of liver tumor (segment) 5 8 6 6 
 
Mean duration of treatment (minutes) 
 
12 
 
14 
 
14 
 
16 
 
pEBV DNA (1 month after treatment) 
(copies / ml) 
Duration of follow-up (months) 
 
0 
 
 
13 
 
0 
 
 
62 
 
0 
 
 
41 
 
0 
 
 
46 
 
Liver status at last follow-up 
 
No recurrence 
 
No recurrence 
 
No recurrence 
 
No recurrence 
 
Overall status at last follow-up 
 
Died from multiple 
bone / lung metastasis 
 
Alive, disease free 
 
Alive, disease free 
 
Alive, disease free 
* American Joint Committee on Cancer ([AJCC], 6
th 
edition 
 
Abbreviations: pEBV DNA: plasma Epstein-Barr virus deoxyribonucleic acid 
 
 
 
outcomes were compared with another cohort of patients treated by 
transcatheter hepatic artery chemoembolization (TACE)
[10]
. The 
number  of  intrahepatic  tumors  were  more  than  3  in  20%  of  the 
patients, and 46.7% of them had the largest tumor measuring more 
than 5cm in size. The authors have shown that surgery was associated 
with a superior 1-, 3- and 5-year overall survival rates. The median 
survival after hepatectomy was 45.2 months. Five out of 15 patients 
have survived more than 5 years and the longest survival was 168.1 
months. Apparently, with aggressive local and systemic treatment, the 
outcome of patients with distant metastasis after treatment for NPC, 
especially for oligometastasis, is not as dismal as previously believed. 
The concept of oligometastasis was first proposed by Hellman et al. as 
an intermediate state (≤5 metastases) between limited primary and 
polymetastatic cancers in which local therapy could achieve long-term 
survival  or  cure,  with   no  restrictions  on  primary  lesions
[17,18]
. 
 
 
Oligo-recurrence was defined as the state that cancer patients have ≤5 
metastatic  or  recurrent  lesions  with  controlled  primary  lesions
[19]
, 
while  sync-oligometastasis  was  proposed  as  the  state  that  cancer 
patients have ≤5 metastatic or recurrent lesions with active primary 
lesions
[20]
. In recent years, several modifications were made to the 
TNM staging system for NPC, but these were focused mainly on the T 
and N components of the system. Based on the evidence that local 
treatment offers the chance of cure in liver metastases in colorectal 
cancer, a new M1 staging system that subdivided the M1 classification 
into 3 subcategories was proposed by the European Colorectal 
Metastases Treatment Group, and it was accepted and incorporated 
into the 7
th 
edition of the American Joint Committee on Cancer (AJCC) 
staging manual
[21]
. There were several recent reports investigating the 
 
 
need for modifying the M1 stage of the TNM staging system for NPC. 
In a retrospective study involving 1016 patients from the Sun Yat-Sen 
University Cancer Center, 33.96% of patients had solitary organ 
metastasis and 16.15% had solitary metastatic lesion in the whole 
body
[22]
. The commonest organs of involvement were bone (53.35%), 
lung (41.34%) and liver (29.72%). It was shown that the state of 
 
 
solitary metastases was one of the independent prognostic predictors 
for  better  survival  compared  with  those  with  multi-organs 
involvement (HR 0.37, P = 0.003). Further study on patients with liver 
metastasis alone from the same institute showed that the survival rates 
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were 62% at 1 year, 31% at 2 years and 21% at 3 years
[23]
. 
Multivariate analysis identified less than 3 metastatic lesions in the 
liver (HR 0.52, P = 0.004) and unilobular metastasis (HR 0.35, 
P<0.001) as the independent predictor for better survival after 
treatment. 
The current investigation is a pilot study of the potential role of 
percutaneous radiofrequency ablation as a minimally invasive local 
treatment for oligometastasis to the liver after previous treatment for 
NPC. All our patient had locoregionally advanced NPC at initial 
diagnosis but none of them had distant metastasis detected. All of 
them demonstrated initial complete response, but were found to have 
either oligometastasis (n = 2) or sync-oligometastasis (n = 2) after a 
mean of 21.3 months from previous radiotherapy. All of them had a 
solitary metastatic lesion in the liver, and the mean size of the 
intrahepatic lesion was much smaller compared to that of the previous 
report treated by partial hepatectomy
[10]
. In our highly selected group 
 
 
of patients with small and solitary liver metastasis from NPC, RFA 
appears to be an effective local treatment with minimal morbidities 
and short hospital stay. The efficacy of the procedure is reflected by 
the prompt return of the plasma EBV DNA level to normal within 1 
month after treatment and the apparent good local control after a 
follow-up duration of 40.5 months. Apart from 1 patient who died 
from pneumonia during systemic chemotherapy for multiple bone and 
lung metastasis, the rest of the patients remained alive and disease free 
at last follow-up. Systemic treatment after RFA/surgery for the liver 
tumor is probably necessary for better tumor control, and further study 
is required to determine the protocol and regimen of chemotherapy in 
such context. 
Conclusion 
Percutaneous RFA is potentially useful as a minimally invasive 
procedure for patients with solitary liver metastasis after radiotherapy 
for NPC.  Further study is  required  to  confirm  its  efficacy and  to 
define the protocol of adjuvant systemic chemotherapy to improve the 
treatment outcome. 
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